Ignite Creation Date:
2025-12-25 @ 4:41 AM
Ignite Modification Date:
2026-03-05 @ 5:42 AM
Study NCT ID:
NCT02543918
Status:
COMPLETED
Last Update Posted:
2017-01-06
First Post:
2015-09-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| I1F-MC-RHCA | OTHER | Eli Lilly and Company | View |